SECURITY AGREEMENT
Exhibit 10.4
by and among
MARINUS PHARMACEUTICALS, INC.,
a Delaware corporation
(the “Company”)
the Company’s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section 24
(each a “Subsidiary Guarantor”
and, together with the Company, each a “Grantor”
and, collectively, the “Grantors”)
SAGARD HEALTHCARE ROYALTY PARTNERS, LP,
as the Investor
(in such capacity, together with its successors and assigns,
the “Investor”).
Dated as of October 28, 2022
TABLE OF CONTENTS
Page
THIS SECURITY AGREEMENT (this “Agreement”), dated as of October 28, 2022, is made by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section 24 (each a “Subsidiary Guarantor” and, together with the Company, each a “Grantor” and, collectively, the “Grantors”), and Sagard Healthcare Royalty Partners, LP, as the Investor under the Revenue Interest Financing Agreement referred to below (in such capacity, together with its successors and assigns, the “Investor”).
WHEREAS, the Company, the Subsidiary Guarantors from time to time party thereto and the Investor are parties to that certain Revenue Interest Financing Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Revenue Interest Financing Agreement”);
WHEREAS, in order to guarantee the indebtedness and other obligations of the Company under the Revenue Interest Financing Agreement, each Subsidiary Guarantor has executed the Revenue Interest Financing Agreement, or will execute and deliver on the date such Subsidiary Guarantor accedes hereto, a Guaranty (as defined in the Revenue Interest Financing Agreement); and
WHEREAS, it is a condition precedent to the purchase, acquisition and acceptance of the Revenue Interest (as defined in the Revenue Interest Financing Agreement) under the Revenue Interest Financing Agreement that the Grantors enter into this Agreement and grant to the Investor the security interests hereinafter provided to secure the obligations of the Company and the Subsidiary Guarantors described below.
NOW, THEREFORE, the parties hereto agree as follows:
“Acceding Grantor” has the meaning set forth in Section 24.
“Accession Agreement” has the meaning set forth in Section 24.
“Books” means all books, records and other written, electronic or other documentation in whatever form maintained now or hereafter by or for any Grantor in connection with the ownership of its assets or the conduct of its business or evidencing or containing information relating to the Collateral, including: (i) ledgers; (ii) records indicating, summarizing, or evidencing any Grantor’s assets (including Inventory and Rights to Payment), business
operations or financial condition; (iii) computer programs and software; (iv) computer discs, tapes, files, manuals, spreadsheets; (v) computer printouts and output of whatever kind; (vi) any other computer prepared or electronically stored, collected or reported information and equipment of any kind; and (vii) any and all other rights now or hereafter arising out of any Contract or agreement between any Grantor and any service bureau, computer or data processing company or other Person charged with preparing or maintaining any of any Grantor’s books or records or with credit reporting, including with regard to any such Xxxxxxx’s Accounts.
“Collateral” has the meaning set forth in Section 2.
“Control Agreement” means an agreement in form and substance reasonably satisfactory to Investor that (i) is entered into among Investor, the financial institution or other Person at which a Deposit Account or Securities Account is maintained, and the Grantor maintaining such Deposit Account or Securities Account, (ii) ensures, to the extent necessary under applicable Law, the perfection of a security interest (with the priority provided for in the Intercreditor Agreement or the Other Intercreditor Agreement, as applicable) in favor of the Investor on such Deposit Account or Securities Account, subject only to Permitted Liens, (iii) provides that, upon written notice from the Investor, such financial institution or other Person shall comply with instructions originated by the Investor directing disposition of the funds in such Deposit Account or Securities Account without further consent by the applicable Grantor, and (iv) may not be terminated by the applicable Grantor without prior written consent of the Investor.
“Excluded Accounts” means (i) deposit accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments to or for the benefit of any Company Party’s employees, (ii) zero balance accounts swept no less frequently than weekly to a Deposit Account subject to a Control Agreement in favor of the First Lien Agent (as defined in the Intercreditor Agreement) or the Investor (including any such account where payments pursuant to Medicaid, Medicare, TRICARE or other state or federal healthcare payor programs are deposited), (iii) accounts (including trust accounts) used exclusively for bona fide escrow purposes, insurance or fiduciary purposes, (iv) cash collateral for Permitted Liens, (v) collateral accounts in respect of any Revenue Interest Financing and (vi) any other deposit accounts established after the Closing Date only for so long as, in the case of this clause (vi), the amounts of deposit therein do not exceed $500,000 in the aggregate.
“Excluded Asset” means:
4
5
provided that the Proceeds of any Excluded Assets that are otherwise Collateral shall not constitute Excluded Assets and shall be subject to the Security Interest.
“Foreign Subsidiary” means any Subsidiary that is not an entity incorporated, formed or organized under the laws of the United States, any state of the United States or the District of Columbia.
“Grantors” has the meaning set forth in the preamble to this Agreement.
“Intellectual Property Collateral” means, to the extent constituting Collateral, the following properties and assets owned or otherwise controlled by any Grantor or in which any Grantor otherwise has any interest, now existing or hereafter acquired or arising:
(i)all Patents, domestic or foreign, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses (including such Patents and Patent licenses as are described in Schedule 2), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;
(ii)all Copyrights, domestic or foreign, together with the underlying works of authorship (including titles), whether or not the underlying works of authorship have been published and whether said Copyrights are statutory or arise under the common law, and all other rights and works of authorship (including the Copyrights described in Schedule 2), all computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying or incorporating any Copyrights, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses, and all other rights, Claims and demands in any way relating to any such Copyrights or works, including royalties and rights to sue for past, present or future infringement, and all rights of renewal and extension of such Copyrights;
(iii)all state (including common law), federal and foreign Trademarks, internet websites, and internet domain names and associated URL addresses, all Licenses relating to any of the foregoing and all income and royalties with respect to any Licenses (including such Trademarks and Trademark licenses as described in Schedule 2), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;
6
(iv)all Technical Information, trade secrets, mask-works, mask-work registrations, mask-work applications, software, confidential and proprietary information, customer lists, advertising materials, operating manuals, methods, processes, know-how, algorithms, formulae, data (including business data and technical data), databases, quality control procedures, product, service and technical specifications, operating, production and quality control manuals, sales literature, drawings, specifications, blue prints, descriptions, inventions, name plates, catalogs;
(v)the entire goodwill of or associated with the businesses now or hereafter conducted by such Grantor connected with and symbolized by any of the aforementioned properties and assets; and
(vi)all accounts, all other proprietary rights, all other Intellectual Property or other similar property and all other intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above.
“Intellectual Property Security Agreement” means each Copyright Security Agreement in substantially the form of Exhibit C, each Trademark Security Agreement in substantially the form of Exhibit D, each Patent Security Agreement in substantially the form of Exhibit E or any amendment thereto and prepared for purposes of recordation with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable.
“Intercreditor Agreement” means that certain Intercreditor Agreement by and between the Investor and Oaktree Fund Administration, LLC, and acknowledged and agreed to by the Company, dated as of the Closing Date, in substantially the form attached to the Revenue Interest Financing Agreement as Exhibit B, as amended, amended and restated, supplement and otherwise modified from time to time in accordance with the terms thereof.
“Invention” means any novel, inventive and useful art, apparatus, method, process, machine (including any article or device), manufacture or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture or composition of matter.
“License” shall mean any written agreement pursuant to which any Grantor grants or receives any license, sublicense, release, covenant not to assert or other right to the extent the foregoing is with respect to any Intellectual Property, including those listed on Schedule 2.
“Material Intellectual Property” means all Intellectual Property, whether currently owned by (or purported to be owned by), or subject to a license, covenant not to sue or similar right to (or purported to be subject to a license, covenant not to sue or similar right to) the Company or any of its Subsidiaries, or acquired, developed, obtained by, or otherwise subject to a license, covenant not to sue or similar right to the Company or any of its Subsidiaries after the date hereof, in each case, the loss of which could reasonably be expected to result in (i) a Material Adverse Effect or (ii) a material adverse effect on any Product Commercialization and Development with respect to ganaxolone.
“Medicaid” means that government-sponsored entitlement program under Title XIX, P.L. 89-97 of the Social Security Act, which provides federal grants to states for medical
7
assistance based on specific eligibility criteria, as set forth on Section 1396, et seq. of Title 42 of the United States Code.
“Medicare” means that government-sponsored insurance program under Title XVIII, P.L. 89-97, of the Social Security Act, which provides for a health insurance system for eligible elderly and disabled individuals, as set forth at Section 1395, et seq. of Title 42 of the United States Code.
“NY UCC” means the Uniform Commercial Code as from time to time in effect in the State of New York.
“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Transaction Document, or sold or assigned an interest in any Transaction Document).
“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Transaction Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.
“Partnership and LLC Collateral” means any and all limited, limited liability and general partnership interests and limited liability company interests of any type or nature (including any such interests in the Company’s direct or indirect Subsidiaries now or hereafter owned by any Grantor), whether now existing or hereafter acquired or arising, including any such interests specified in Schedule 3.
“Pledge Supplement” has the meaning specified in Section 3(i).
“Pledged Collateral” means, to the extent constituting Collateral, any and all (i) Pledged Shares; (ii) additional capital stock or other Equity Interests of the direct Subsidiaries of any Grantor, whether certificated or uncertificated; (iii) other Investment Property of any Grantor; (iv) warrants, options or other rights entitling any Grantor to acquire any interest in Equity Interests or other securities of such Subsidiaries or any other Person; (v) Partnership and LLC Collateral; (vi) Instruments and Pledged Debt Securities; (vii) securities, property, interest, dividends and other payments and distributions from time to time received, receivable or otherwise distributed in respect of, or issued as an addition to, in redemption of, in renewal or exchange for, in substitution or upon conversion of, or otherwise on account of, any of the foregoing; (viii) certificates and instruments now or hereafter representing or evidencing any of the foregoing; (ix) rights, interests and Claims with respect to the foregoing, including under any and all related agreements, instruments and other documents, and (x) cash and non-cash proceeds of any of the foregoing, in each case whether presently existing or owned or hereafter arising or acquired and wherever located, and as from time to time received or receivable by, or otherwise paid or distributed to or acquired by, any Grantor.
8
“Pledged Collateral Agreements” has the meaning specified in Section 5(p)(i).
“Pledged Debt Securities” means, to the extent constituting Collateral, any and all the debt securities and promissory notes and other instruments evidencing Indebtedness for borrowed money with a principal amount in excess of $100,000 held by such Grantor on the date hereof (including all such debt securities listed opposite the name of such Grantor on Schedule 1) and not an Excluded Asset and (ii) any debt securities or promissory notes or other instruments evidencing Indebtedness for borrowed money in the future issued to such Grantor and not an Excluded Asset.
“Pledged Shares” means, to the extent constituting Collateral, all of the issued and outstanding shares of Equity Interests, whether certificated or uncertificated, of the Company’s direct or indirect Subsidiaries, now or hereafter owned by any Grantor, including each Subsidiary identified on Schedule 3 (as amended or supplemented from time to time).
“Proceeds Account” has the meaning set forth in Section 10(c).
“Product Related Information” means, with respect to any Product, all books, records, lists, ledgers, files, manuals, correspondence, reports, plans, drawings, data and other information of every kind (in any form or medium), and all techniques and other know-how, owned or possessed by the Company Parties or any of their respective Subsidiaries that are necessary or useful for any Product Commercialization and Development relating to such Product, including (i) brand materials and packaging, customer targeting and other marketing, promotion and sales materials and information, referral, customer, supplier and other contact lists and information, product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training materials and other marketing, sales and promotional information and (ii) clinical data, information included or supporting any Product Authorization (as defined in the Oaktree Credit Agreement), any regulatory filings, updates, notices and correspondence (including adverse event and other pharmacovigilance and other post-marketing reports and information, etc.), technical information, product development and operational data and records, and all other documents, records, files, data and other information, used in connection with the Product Commercialization Development for such Product.
“Quarterly Reporting Date” means each date on which a certificate is required to be delivered pursuant to Section 6.10 of the Revenue Interest Financing Agreement.
“Recipient” means the Investor or any other recipient of any payment to be made by or on account of any Obligation.
“Registered Intellectual Property Collateral” means, to the extent constituting Collateral, all Intellectual Property Collateral covered by issued patent, copyright or trademark registrations, or pending applications or applications for patent, copyright or trademark registration, at the United Stated Patent and Trademark Office or the United States Copyright Office.
“Rights to Payment” means any and all of any Grantor’s Accounts and any and all of any Grantor’s rights and Claims to the payment or receipt of money or other forms of consideration of any kind in, to and under or with respect to its Chattel Paper, Documents, General
9
Intangibles, Instruments, Investment Property, Letter-of-Credit Rights, Proceeds and Supporting Obligations.
“Secured Obligations” means all Obligations (as defined in the Revenue Interest Financing Agreement) other than inchoate indemnification and expense reimbursement obligations for which no claim has been made.
“Technical Information” means all Product Related Information and, with respect to any Products or Product Commercialization and Development, all related know-how, trade secrets and other proprietary or confidential information, any information of a scientific, technical, or business nature in any form or medium, Invention disclosures, all documented research, developmental, demonstration or engineering work, and all other technical data and information related thereto.
10
Notwithstanding the foregoing or anything herein to the contrary, (x) in no event shall the “Collateral” include or the Security Interest attach to any Excluded Asset and (y) the representations and covenants set forth herein regarding the assets of the Grantors shall apply solely to such assets of the Grantors that constitute “Collateral”.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
The Investor agrees that, except upon the occurrence and during the continuation of an Event of Default, it shall not exercise the power of attorney, or any rights granted to the Investor, pursuant to clauses (b) through (q). The foregoing power of attorney is coupled with an interest and irrevocable so long as the Secured Obligations have not been paid and performed in full. Each Grantor hereby ratifies, to the extent permitted by Law, all that the Investor shall lawfully and in good faith do or cause to be done by virtue of and in compliance with this Section 7.
27
The Investor shall give each applicable Grantor not less than 10 days’ written notice (which each Grantor agrees is reasonable notice within the meaning of Section 9-611 of the NY UCC or its equivalent in other jurisdictions) of the Investor’s intention to make any sale of Collateral. Such notice, in the case of a public sale, shall state the time and place for such sale and, in the case of a sale at a broker’s board or on a securities exchange, shall state the board or exchange at which such sale is to be made and the day on which the Collateral, or portion thereof, will first be offered for sale at such board or exchange. Any such public sale shall be held at such time or times within ordinary business hours and at such place or places as the Investor may fix and state in the notice (if any) of such sale. At any such sale, the Collateral, or portion thereof, to be sold may be sold in
28
one lot as an entirety or in separate parcels, and by the Investor in its own right or by one or more agents or contractors, upon any premises owned, leased or occupied by any Grantor, the Investor or any such agent or contractor, and any such sale may include any other property, in each case, as the Investor may (in its sole and absolute discretion) determine. The Investor shall not be obligated to make any sale of any Collateral if it shall determine not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. The Investor may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for future delivery, the Collateral so sold may be retained by the Investor until the sale price is paid by the purchaser or purchasers thereof, but the Investor shall not incur any liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At any public (or, to the extent permitted by law, private) sale made pursuant to this Agreement, the Investor may bid for or purchase, free (to the extent permitted by applicable law) from any right of redemption, stay, valuation or appraisal on the part of any Grantor (all said rights being also hereby waived and released to the extent permitted by applicable law), the Collateral or any part thereof offered for sale and may make payment on account thereof by using any claim then due and payable to the Investor from any Grantor as a credit against the purchase price, and the Investor may, upon compliance with the terms of sale, hold, retain and dispose of such property without further accountability to any Grantor therefor. For purposes hereof, a written agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof; the Investor shall be free to carry out such sale pursuant to such agreement and no Grantor shall be entitled to the return of the Collateral or any portion thereof subject thereto, notwithstanding the fact that after the Investor shall have entered into such an agreement all Events of Default shall have been remedied and the Obligations shall have been indefeasibly paid in full in cash. As an alternative to exercising the power of sale herein conferred upon it, the Investor may proceed by a suit or suits at law or in equity to foreclose this Agreement and to sell the Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having competent jurisdiction or pursuant to a proceeding by a court-appointed receiver. Any sale pursuant to the provisions of this Section 10(a) shall be deemed to conform to the commercially reasonable standards as provided in Section 9-610(b) of the NY UCC or its equivalent in other jurisdictions. The Investor shall not be required to marshal any present or future Collateral or to resort to such Collateral in any particular order.
29
30
31
32
33
executed signature page of this Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.
Upon the consummation of any transaction permitted under the Revenue Interest Financing Agreement as a result of which such Grantor ceases to be a Subsidiary Guarantor, such Grantor shall be automatically released from its obligations hereunder arising after the date on which such Grantor ceases to be a Subsidiary Guarantor and the security interests created hereunder in the Collateral of such Grantor shall be automatically released.
Upon any sale, lease, transfer or other disposition by any Grantor of any Collateral that is permitted under the Revenue Interest Financing Agreement to any Person that is not another Grantor, the security interest in such Collateral shall be automatically released.
34
In addition, in connection with any Permitted Licenses, the Investor shall, at the request of any Grantor, negotiate and enter into a non-disturbance agreement and other similar agreements in form and substance reasonably satisfactory to the Investor.
Notwithstanding the foregoing, the Investor shall not be required to take any action under this Section 25 unless the applicable Grantor shall have delivered to the Investor together with such request, which may be incorporated into such request, a certificate of an authorized officer of the Company or such Grantor in form and substance reasonably satisfactory to the Investor which certifies that the transaction giving rise to such termination or release is permitted by the Revenue Interest Financing Agreement and was, or will concurrently with the release be, consummated in compliance with the Transaction Documents.
[Remainder of page intentionally left blank; signature pages follow]
35
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.
GRANTOR:
Marinus Pharmaceuticals, INC.
By:/s/ Xxxxxx Xxxxxxxxx
Name: Xxxxxx Xxxxxxxxx
Title: Chief Financial Officer
36
INVESTOR:
SAGARD HEALTHCARE ROYALTY PARTNERS, LP
By: Sagard Healthcare Royalty Partners GP LLC
Its: General Partner
By:Xxxxx Xxxxx
Name: Xxxxx Xxxxx
Title: Manager
By:Xxxxx Xxxxx
Name: Xxxxx Xxxxx
Title: General Counsel and Secretary
37
1. | Locations of Chief Executive Office and other Locations, including of Collateral |
2. | Jurisdiction of Organization of each Grantor |
3. | Trade Names and Trade Styles of each Grantor; Other Corporate, Trade or Fictitious Names of each Grantor; Etc. |
4. | Deposit Accounts of each Grantor |
5. | Investment Property of each Grantor |
6. | Instruments and Chattel Paper of each Grantor |
7. | [Reserved] |
Inventory of each Grantor Stored with Warehousemen or on Leased Premises, Etc.
8. | Letter-of-Credit Rights of each Grantor |
9. | Pledged Debt Securities of each Grantor |
1
TRADEMARKS
2
COPYRIGHTS
3
SCHEDULE 4
FINANCING STATEMENTS
SUPPLEMENT TO SCHEDULE 3
TO THE SECURITY AGREEMENT
PARTNERSHIP AND LLC COLLATERAL
3
Schedule 1
COPYRIGHTS
5
Schedule 1
TRADEMARKS
7